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Abstract: 
The ability of disseminated cancer cells to evade the immune response is a critical step for efficient 
metastatic progression. Protection against an immune attack is often provided by the tumor 
microenvironment that suppresses and excludes cytotoxic CD8
+
 T cells. Pancreatic ductal 
adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the 
immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not 
completely understood. In this study we find that macrophage-derived granulin contributes to cytotoxic 
CD8
+
 T cell exclusion in metastatic livers. Granulin expression by macrophages was induced in 
response to colony-stimulating factor-1. Genetic depletion of granulin reduced the formation of a 
fibrotic stroma, thereby allowing T cell entry at the metastatic site. While metastatic PDAC tumors are 
largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin-depleted tumors restored the anti-
tumor immune defense and dramatically decreased metastatic tumor burden. These findings suggest 
that targeting granulin may serve as a potential therapeutic strategy to restore CD8
+
 T cell infiltration 
in metastatic PDAC, thereby converting PDAC metastatic tumors, which are refractory to immune 
checkpoint inhibitors, into tumors that respond to immune checkpoint inhibition therapies.  
 
Introduction  
The ability of the immune system to identify and destroy cancer cells is a primary defense 
mechanism against cancer. CD8
+
 cytotoxic T cells, also known as cytotoxic T cells (CTLs), are key 
effectors of the immune response against cancer (1) and their presence in tumors is associated with a 
good clinical outcome in many tumor types, including ovarian, colon, breast, and pancreatic cancer 
(2-4). The importance of effector CD8
+
 T cell mediated anti-tumor immune response in oncogenesis is 
demonstrated by the clinical success of immunotherapies (1,5). Particularly, the use of immune 
checkpoint inhibitors has recently been shown to be beneficial for many types of cancers, with anti-
programmed cell death protein 1 (PD-1) inhibitors being one of the leading candidates (6). However, 
immune checkpoint inhibitors only work if CD8
+
 T cells are infiltrated in to tumors. Pancreatic tumors 
are particularly poorly infiltrated by CD8
+
 T cells and thus, inhibition of immune checkpoint receptors 
alone did not show any benefit in pancreatic cancer patients (7,8). Pancreatic cancer is characterized 
by a rich and desmoplastic tumor stroma, also called tumor microenvironment (TME), identified by 
high numbers of activated fibroblasts, collagen deposition, and extensive myeloid cell infiltration, 
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which all together critically impact the disease progression (9) and its response to therapy (10-12). 
The TME is also thought to be a major barrier to CD8
+
 T cell infiltration in pancreatic tumors (13,14) 
and it is necessary to overcome this immune/fibrotic-protective barrier for the successful use of 
immune checkpoint inhibitors (15,16).  
Macrophages represent a major component of tumor infiltrating immune cells and depending on 
the activation signals, macrophages can acquire a spectrum of phenotypic states. In respect to 
cancer, macrophages can be polarized into M1-like inflammatory macrophages that  activate a 
tumoricidal immune response (hereafter also referred to as M1-like), or into anti-inflammatory, 
immunosuppressive macrophages (hereafter also referred to as M2-like) that potently suppress other 
anti-tumor immune effector cells and thereby promote tumor progression (15,17,18). High density of 
macrophages, especially those exhibiting an immunosuppressive M2-like phenotype, correlates with 
poor clinical outcome in most human cancers (17). Accordingly, inhibition of myeloid cell recruitment 
into tumors have resulted in increased CD8
+
 T cell infiltration and decreased tumor burden in mouse 
models and early-phase clinical trials (15,18-23). Yet, the mechanisms by which macrophages 
regulate T cell infiltration is only beginning to emerge. 
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive metastatic disease. Currently, 
surgical resection is the best treatment option for PDAC patients, but, unfortunately, by the time 
PDAC is diagnosed, the majority of patients (~ 80%) present with non-resectable metastatic cancer. 
Moreover, more than 60% of the patients whose tumors are removed, relapse with distant hepatic 
recurrence within the first 24 months after surgery (12,24). Thus, a better understanding of the 
mechanisms underlying the metastatic process in pancreatic cancer is critical to improve treatment 
and patient survival. We and others have recently identified that a desmoplastic TME also exists at 
the metastatic site in PDAC, which is mainly the liver, and that this fibro-inflammatory reaction is 
required for metastatic growth (25,26). However, whether and how the metastatic TME affects CD8
+
 T 
cell infiltration and function in the metastatic liver remains unexplored. Here, we found that 
macrophage-derived granulin is a key protein that supports CD8
+
 T cell exclusion and resistance to 
anti-PD-1 (αPD-1) treatment. In fact, we show that depletion of granulin converts PDAC metastatic 
tumors, which are refractory to anti-PD1 treatment, into tumors that respond to αPD-1. Our findings 
provide pre-clinical evidence that support the rational for targeting granulin in combination with the 
immune checkpoint blocker PD-1 for the treatment of metastatic PDAC.  
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Material and Methods 
Cells  
Murine pancreatic cancer cells KPC FC1199, from here on referred as KPC, were generated in the 
Tuveson lab (Cold Spring Harbor Laboratory, New York, USA) isolated from PDA tumor of Kras
G12D/+
; 
p53
R17H/+
; Pdx1-Cre mice of a pure C57BL/6 background and authenticated as previously reported 
(27). The murine C57BL/6 Panc02 pancreatic ductal carcinoma cell line was obtained from the NCI 
DCTD Tumor Repository, NIH. Panc02
luc/zsGreen
 or KPC
luc/zsGreen
 cells were generated by using pHIV 
Luc-zsGreen (gift from B. Welm, University of Utah, USA, Addgene plasmid no.39196) lentiviral 
particle infection. Infected cells were selected for high zsGreen expression levels using flow cytometry 
cell sorter (ARIA, BD). Immortalized hepatic stellate cells were obtained by isolating hepatic stellate 
cells from p21
-/-
 mice (C57BL/6), kindly provided by T. Sakai’s laboratory, University of Liverpool, 
UK and were authenticated as previously described (28).  
All cells were maintained at a minimal passage number (< p8) to allow initial expansion prior to use 
for in vitro and in vivo experiments. All cells were routinely tested negative for the presence of 
mycoplasma contamination. None of the cell lines used in this manuscript is listed in the ICLAC and 
NCBI Biosample database of misidentified cell lines.  
Mice 
6-8 weeks old female C57BL/6 mice were purchased from Charles River. Grn
-/-
 mice (B6(Cg)-
Grn
tm1.1Aidi
/J) and tdTomatoRed mice (B6.129(Cg)-Gt(ROSA)26Sor
tm4(ACTB-tdTomato,-EGFP)Luo
/J)  both on 
the C57BL/6 genetic background were purchased from The Jackson Laboratory. Kras
G12D/+
; 
p53
R172H/+
; Pdx1-Cre mice were purchased from CRUK, Cambridge Research Institute, Cambridge. 
All animal experiments were performed in accordance with current UK legislation under an approved 
project license PPL 40/3725 (M.C. Schmid). Mice were housed under specific pathogen-free 
conditions at the Biomedical Science Unit at the University of Liverpool. For tumor studies, female 
animals age 6-8 weeks were used. Animals were randomly assigned to experimental groups. The 
investigators were not blinded to allocation during experiments and outcome assessments. 
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In vivo animal studies  
Liver experimental metastasis was performed by implanting 1x10
6 
KPC 
luc/zsGreen  
or Panc02
 luc/zsGreen  
in 
25 μl PBS into the spleen of immunocompetent isogenic C57BL/6 mice using a Hamilton 29 G syringe 
as previously described (25,26). For selected experiments, macrophages were depleted using CSF-1 
neutralizing antibody (BioXCell, clone 5A1,) or CSF-1R inhibitor (Selleckchem, BLZ945). Anti-CSF-1 
antibody was administered via intraperitoneal (i.p.) injection every 5 days with the first injection 
containing 1 mg and subsequent injections containing 0.5 mg for a total of 3 injections in 14 days 
(early time point treatment, d7) and 2 injections in 10 days (late time point treatment, d14) . Rat IgG1 
(BioXCell, clone HRPN) was used as isotype control. CSF-1R inhibitor BLZ945 was administered 
daily at a concentration of 200 mg/kg in 20% Captisol (Ligand Pharmaceuticals) by oral gavage. 20% 
Captisol was used as vehicle control. For immune checkpoint blockade, PD-1 antagonist (BioXCell, 
clone RMP-1) or Rat IgG2 (BioXCell, clone 2A3) isotype control were administered every 3 days by 
i.p. injection at 250 µg/dose for a total of 4 injections in 14 days (early time point treatment, d7) and  3 
injections in 10 days (late time point  treatment, d14). In the experiments in which CSF-1 and PD-1 
inhibitory antibodies have been used in combination, αPD-1 treatment was started 3 days after the 
first dose of CSF-1 inhibitor. For T-cell depletion study, anti-CD8 (αCD8, BioXCell, clone 2.43, 200 
µg/dose) was injected by i.p. 2 days prior intrasplenic implantation of KPC
luc/zsGreen
 cells into mice on 
the day of KPC
luc/zsGreen 
implantation followed by injections every 4 days for the duration of the 
experiment. As isotype control, Rat IgG2 (BioXCell, clone LTF-2; 200ug/dose) was used. To validate 
the effect of hypoxia in metastatic liver mice, Digoxin (Sigma Aldrich) was used at concentration of 2 
mg/kg by i.p. for a total of 2 injections in 3 days. To target fibrosis, Calcipotriol (Tocris Bioscience) was 
administered daily by i.p. injection at a concentration of 60 μg/kg for a total of 10 days. PD-1 
antagonist (BioXCell, clone RMP-1, 250 μg/dose) treatment regimen was started after 3 Calcipotriol 
injections and continued for 10 days with an injection every 3 days. To assess the presence of 
hypoxic area in healthy and metastatic livers, the Hypoxyprobe
TM 
RED 549 Kit (Hypoxyprobe, hpi) 
was used according to the manufacturer’s instruction. Briefly, 1.5 mg/mouse of Hypoxtprobe
TM
-1 
(pimonidazole HCl) solution was administered via i.p.. Livers from injected mice were harvested after 
60 min and stained with RED 549 dye-Mab1, a dye conjugated mouse IgG1 monoclonal antibody. 
Treatment trials were initiated when transplanted tumors reached a mean volume of approximately 40 
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mm
3
 and 180 mm
3
 7 and 14 days after implantation, respectively. Time points for treatment analysis 
were preselected based on the expected window of efficacy (after 1-2 weeks of treatment).  
Metastatic tumor burden quantification 
Liver metastatic tumor burden was assessed, both in vivo and ex-vivo, by measuring bioluminescence 
signal (IVIS, Perkin Elmer) generated by KPC
luc/zsGreen
 or Panc02
 luc/zsGreen 
cells. Bioluminescence 
signal was detected by intraperitoneal injection (i.p.) of Beetle luciferin (Promega; 3 mg/mouse) and 
quantified as total flux (photons/sec). For some experiments, change in tumour volume in response to 
inhibitory Abs or drug treatment was assessed by 9.4 Tesla (T) horizontal bore Biospec MRI scanning 
(Bruker Biospin, Inc.). Mice livers were scanned in vivo before and after treatment using a T2-
TurboRARE acquisition protocol. MRI images were acquired in coronal plane with 0.5 mm thickness 
and 0.1 mm spacing between each slice. A set of 23 slices was acquired to monitor the entire liver 
volume. Metastatic tumor volume was quantified by Image J software. Percentage change in 
metastatic tumor burden (before and after treatment) was obtained by calculating the sum of tumor 
area of all slices spanning the liver and multiplying it by 0.6 mm (inter-slice distance). The MRI 
acquisition used the following parameters: 2500 ms TR; 24 ms TE; 30x30 mm FOV; 240 x 240 image 
size. At indicated endpoints, liver metastatic lesions size and frequency were quantified based on 
haematoxylin and eosin staining of paraffin-embedded liver sections. Zeiss microscope and ZEN 
imaging software was used. 
Preparation of conditioned media (CM) 
Conditioned medium from Panc02, KPC cancer cells, bone marrow derived macrophages (BMM) and 
activated immortalized hepatic stellate cells (HSC) was generated according to previous reports (26). 
Briefly, the medium was removed from 70 % confluent cells and the cells were washed three times 
with PBS before addition of serum-free medium. Cells were incubated for 18-24h in serum-free 
medium and then collected and filtered through 0.45 µm filters before use. 
Granulin gene expression analysis in bone marrow derived macrophages (BMMs)  
Primary murine macrophages were generated by flushing the bone marrow from the femur and tibia 
of C57BL/6 mice followed by incubation for five days in DMEM containing 10 % FBS and 10ng ml
-1 
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murine M-CSF (Peprotech). BMM were subsequently stimulated with DMEM containing 2% serum in 
the presence or absence of murine recombinant M-CSF (Peprotech) for 24 hour. Alternatively, BMMs 
were stimulated with KPC or Panc02 CM for 24 hours in the presence of absence of αCSF-1 inhibitory 
antibody (BioXCell; [2.5 g/ml]). BMMs were finally lysed in RLT buffer + β-Mercaptoethanol and 
Granulin expression was assessed by qPCR. 
ELISA 
Assessment of granulin secretion: Primary murine bone marrow macrophages (BMMs) were 
generated as described above and subsequently stimulated with DMEM containing 2 % serum in the 
presence of murine recombinant M-CSF ([20 ng/ml]; Peprotech), IFNγ [20 ng/ml] and LPS [100 ng/ml 
(Peprotech and Sigma Aldrich, respectively), IL-10 ([20 ng/ml]; Peprotech), IL-13 ([20 ng/ml]), IL-4 
([20 ng/ml]; Peprotech) for 24 hours. Supernatant was collected to assess granulin protein level by 
ELISA (LifeSpan BioScience, LSBio). For assessing granulin secretion under hypoxic culture 
conditions, BMMs were maintained at 37 °C with 5% CO2 and 1% O2 (Don Whitley Scientific, Shipley, 
UK; Hypoxystation-H35). In all other cases, BMM were cultured under normoxic conditions (37 °C 
with 5 % CO2 and ~18-21 % O2). BMMs were cultured for 24 hours under normoxic and hypoxic 
conditions in the presence or absence of 10 ng/ml murine recombinant CSF-1 (Peprotech). For 
Dimethyloxaloylglycine (DMOG) treatment, cells were culture under normoxia condition in media 
supplemented with 0.5 mM DMOG (Enzo Laboratories, Farmingdale, NY, USA) for 24 hours. 
Supernatant was collected to assess granulin protein level by ELISA (LifeSpan BioScience, LSBio). 
Assessment of M-CSF-1 secretion: Conditioned media from Panc02, KPC cancer cells and BMMs 
was obtained to measure the production of murine M-CSF by Quantikine ELISA kit (R&D System) 
according to the manufacturer’s instruction. 
Adoptive transfer experiments 
For T cell adoptive transfer, experimental metastasis was induced by intrasplenic implantation of 
1x10
6
 KPC
luc/zsGreen
 cells into tdTomatoRed+, WT, and Grn
-/-
 mice.  After 13 days, tumor bearing 
tdTomatoRed+ mice were euthanized and spleens were dissected to isolate CD8
+ 
T cells (Miltenyi, 
CD8a
+
 T cell isolation Kit). Isolated CD8
+ 
T cells were stimulated with Dynabeads Mouse T- Activator 
CD3/CD28 (Life Technology) following manufacturer’s instruction, and incubated for 24 hours at 37°C. 
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The next day, 1.5x10
6  
tdTomoatoRed
+
 CD8
+
 T cells were injected into the tail vein of tumor bearing 
WT and Grn
-/-
 mice. After 24 hours, mice were sacrificed and livers were collected and embedded in 
Optimal Cutting Temperature (OCT) medium. 5 μm liver sections were stained for DAPI (Life 
Technology, 1:500) and spatial localization of adoptive transferred dtTomatoRed
+
 CD8+ T cells was 
assessed by fluorescence microscopy measuring dtTomato Red
+
 signal.  
For MAMs adoptive transfer, experimental metastasis was induced by intrasplenic implantation of 
1x10
6
 KPC
luc/zsGreen
 cancer cells. Mice were treated with CSF-1 and PD-1 inhibitory Abs starting 7 or 
14 days after cancer cells implantation. At day 24, metastatic livers from sacrificed mice were 
dissected to isolate F4/80
+
 cells (Miltenyi, F4/80
+
 isolation Kit). 1x10
6
 F4/80
+
 isolated cells were then 
injected into the tail vein of mice bearing experimental metastasis at day 7. After 5 days, injected  
mice were euthanized and liver were harvested and analyzed further. 
Bone marrow transplantation 
Bone marrow transplantation was performed by reconstituting the bone marrow of lethally irradiated 
(10 Gy) female, 6-week-old C57BL/6 mice by tail vein injection of 5 × 10
6
 total bone marrow cells 
isolated from Grn
−/−
 mice or WT mice. After 4 weeks, engraftment of Grn
−/−
 bone marrow was 
assessed by genomic DNA PCR according to The Jackson Laboratory protocol on peripheral blood 
cells from fully recovered bone-marrow-transplanted mice. After confirmation of successful bone 
marrow reconstitution, mice were enrolled in tumour studies. 
Flow cytometry and cell sorting 
Single cell suspensions from murine livers were prepared by mechanical and enzymatic disruption in 
Hanks Balanced Salt Solution (HBSS) with 1 mg/mL Collagenase P (Roche) as previously described 
(26). Briefly, cell suspensions were centrifuged for 5 minutes at 1200 rpm, resuspended in HBSS and 
filtered through a 500 m polypropylene mesh (Spectrum Laboratories). Cell suspensions were 
resuspended in 1ml 0.05 % trypsin and incubated at 37° C for 5 minutes. Cells were filtered through a 
70 m cell strainer and resuspended in PBS + 0.5% BSA. Cells were blocked for 10 minutes on ice 
with FC block (BD Pharmingen, Clone 2.4 G2,) and then stained with Sytox-blue viability marker (Life 
Technologies) and conjugated with antibodies against CD45 (Clone 30F-11), F4/80 (Clone BM8), 
CD8 (Clone 53-6.7), CD206 (Clone C068C2), PD-1(Clone 29F.1A12), CD69 (Clone H1.2F3), CD3 
9 
 
(Clone 145-2C11),  CD11b (Clone M1/70), Ly6C ( Clone HK 1.4), Ly6G (Clone  1A8), IFN (Clone 
XMG1.2), Ki67 (Clone 16A8); Ly6G (Clone 1A8) all purchased from Biolegend; Granzyme B 
(eBioscience, clone NGZB). For intracellular staining, cells were first fixed (eBioscience, IC fixation 
buffer) and permeabilized (eBioscience, 1x permeabilization buffer).  
To assess IFN expression levels in metastasis derived CD8
+
 T cells,  magnetically isolated CD8a
+
 T 
cells from metastatic livers were stimulated with 50 ng/ml phorbol 12-myristate 13- acetate (PMA) 
(Sigma Aldrich) and 1 g/ml of Ionomycin (Sigma Aldrich) for 5 hours at 37° C in the presence of 
Brefeldin A (eBioscience, 1:100) and subsequently stained for IFNγ. 
Flow cytometry was performed on a FACS Canto II (BD Bioscience) and FACS cell sorting was 
carried out using FACS Aria (BD Bioscience). Cells were sorted directly in RLT buffer + β-
Mercaptoethanol accordingly with the manufacturer’s instruction for RNA isolation (Qiagen). 
Magnetic beads isolation of cells  
Samples for magnetic bead isolation were prepared from livers as described above for preparation of 
flow cytometry samples. Samples were stained and CD8a
+
 or F4/80
+
 cells were isolated according to 
the manufacturer’s instruction (Miltenyi).  
In vitro T-cell activation assay 
Primary splenocytes were obtained from spleens of naïve C57BL/6 mice. Dissected spleens were 
dissociated in MAC buffer and passed through a 70 µm cell strainer to obtain a single cell suspension. 
Cells were centrifuged (400 x g) and red blood cells were lysed using 1x Red blood lysis buffer 
(Biolegend). Obtained splenocytes were cultured in RPMI supplemented with 10% FBS. For T cell 
activation assays, splenocytes were stimulated using Dynabeads Mouse T- Activator CD3/CD28 (Life 
Technology). Activated splenocytes (S) were then co-cultured with bone marrow derived 
macrophages (BMMs) from WT and Grn
-/-
 mice or with macrophages (M) magnetically isolated cells 
from  day 6 and day 14 metastasis bearing livers (4:1 ratio, S: M). Cells were plated in 96 well plates 
and incubated at 37°C for 24h. Subsequently, Brefeldin A (eBioscience, 1:100) was added to the cells 
for 5h. Cells were then harvested and stained with CD8 (Biolegend, clone 53-6.7) and IFNγ 
(Biolegend, Clone XMG1.2) antibodies and analyzed by flow cytometry. For some experiments, 
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recombinant mouse Progranulin protein (recGrn) (R&D systems; [1 µg/ml]) and mouse Periostin 
neutralizing antibody (R&D systems; [1 µg/ml]) were used. 
In vitro T- cell proliferation Assay  
For T cell proliferation assay, splenocytes derived from naïve C57BL/6 mice were labelled with 5 μM 
Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) (Biolegend) and incubated for 10 minutes at 
37°C in the dark. Cells were then resuspended in RPMI 1640 supplemented with 10% FBS and 
stimulated with Dynabeads Mouse T-Activator CD3/CD28. Activated splenocytes (S) were then co-
cultured with bone marrow derived macrophages (BMMs) from WT and Grn
-/-
 mice or with 
macrophages (M) magnetically isolated cells from  day 6 and day 14 metastasis bearing livers (4:1 
ratio, S: M). Cells were plated in 96 well plates and incubated at 37°C for 72 hours. Subsequently, 
cells were harvested and stained with CD8 antibody (Biolegend, clone 53-6.7). Proliferating CD8+ T 
cells were tracked by flow cytometry. For some experiments, recombinant mouse Progranulin protein 
(R&D systems; [1 µg/ml]) and mouse Periostin neutralizing antibody (R&D systems, [1 µg/ml]) were 
used. 
RT-qPCR 
Total RNA purification was performed with the RNeasy kit (Qiagen) and cDNA was generated using 
QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturer’s instructions. 500 ng of 
total RNA was used to generate cDNA. Quantitative polymerase chain reaction (qPCR) was 
performed using 5x HOT FIREPol EvaGreen qPCR Mix Plus (ROX) (Solis Biodyne) on an MX3005P 
instrument (Stratagene). Three-step amplification was performed (95° C for 15 seconds, 60° C for 20 
seconds, 72° C for 30 seconds) for 45 cycles. Relative expression levels were normalized to Gapdh 
expression according to the formula 2^− (Ct gene of interest – Ct Gapdh). Fold increase in expression 
levels were calculated by comparative Ct method 2^- (ddCt). 
The following QuantiTect Primers Assays were used to assess mRNA levels: Gapdh 
(Mm_Gapdh_3_SG; QT01658692), Cxcl10 (Mm_Cxcl10_1_SG; QT00093436),  Cd86 
(Mm_Cd86_1_SG; QT01055250), Ifng (Mm_Ifng_1_SG; QT01038821), Il12 (Mm_Il12b_1_SG; 
QT00153643), H2-Aa (Mm_H2-Aa_1_SG; QT01061858), Retnla (Mm_Retnla_1_SG; QT00254359), 
Tgfb (Mm_Tgfb1_1_SG; QT00145250), Il10 (Mm_Il10_1_SG; QT00106169), Arginase 
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(Mm_Arg1_1_SG; QT00134288), Gzmb (Mm_Gzmb_1_SG; QT00114590), Tnf (Mm_Tnf_1_SG; 
QT00104006), Prf1 (Mm_Prf1_1_SG; QT00282002), Mrc1 (Mm_Mrc1_SG; QT00103012), Granulin 
(Mm_Grn_1_SG; QT01061634). All primers were purchased from Qiagen. 
Immunofluorescence  
Murine liver tissues were fixed using a sucrose gradient method to preserve the zsGreen 
fluorescence. Briefly, livers were fixed in 4% Formaldehyde + 10% sucrose in PBS for 4 hours and 
then transferred to 20% sucrose in PBS for 8-10 hours. Tissues were transferred into 30% sucrose for 
an additional 8-10 hours, embedded in OCT medium and stored at -80°C.  
For immunofluorescence staining 5 μm liver sections were permeabilized by 0.1% TritonX-100 (Sigma 
Aldrich) for 10 minutes. Unspecific bindings were prevented by using PBS +8% Normal goat serum 
for 1 hour at RT. Tissue sections were incubated overnight at 4 °C with the following antibodies: 
αSMA (Abcam, ab5694, 1:100); Relm-α (Abcam, 39626, 1:100); Cleaved- Caspase 3 (Cell Signalling, 
9661, 1:100); CSF1R (Santa Cruz Biotechnology, clone c-20, 1:100). The next day, tissue sections 
were washed in PBS and stained with the secondary antibody goat anti-rabbit conjugated to 
AlexaFluo594 (Abcam, 1:500) and DAPI (Life Technologies, 1:500) for 1 hour at RT. Zs 
Green/Luciferase transfected cells were detected by their intrinsic signal. Sections were finally 
mounted using Dako Fluorescent Mounting Medium. 
Immunofluorescence staining was also performed in some cases on tissue sections obtained from 
livers directly embedded in OCT. In this case tissue sections were fixed in ice-cold acetone for two 
minutes and permeabilized with 0.1% TritonX-100. Sections were washed and incubated overnight at 
4°C with the primary antibodies: CD8 (Biolegend, clone 53-6.7, 1:100), F480 (Biolegend, clone BM8, 
1:100). The next day, tissue sections were washed in PBS and stained with the secondary antibody 
goat anti-rabbit conjugated to AlexaFluo594 (Abcam, 1:500); goat anti-rat conjugated to AlexaFluo488 
(Abcam, 1:500) and DAPI (Life Technologies, 1:500) for 1 hour at RT. All tissue sections were imaged 
using an Axio Observer Light Microscope with the Apotome.2 (Zeiss) and quantified using the Zen 
Software (Zeiss). Quantification of intrametastatic (IM) and peripheral (P) CD8
+
 T cells was performed 
using Nis Elements, Advanced Research software (Nikon). Peripheral area of metastatic lesions was 
defined as the outer 40 % of the total lesion area.  
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Immunohistochemistry analysis  
Deparaffinization and antigen retrieval was performed using an automated DAKO PT-link. Paraffin-
embedded human and mouse liver metastatic sections were immunostained using the DAKO 
envision+system-HRP. Tissue sections were incubated overnight at 4°C with primary antibodies: 
SMA (Abcam, ab5694, 1:200); CD8 (Dako, Clone 144b, 1:100); Cytokeratin 19 (Abcam, ab53119, 
1:100); Granzyme B (Dako, 1:50); PD-1 (CD279) (Abcam, ab52587, 1:100); CD3 (Abcam, ab16669, 
clone SP7, 1:100); Granulin (R&D Systems, MAB25571, 1:50); iNOS ( Abcam, ab15323, 1:100); MHC 
II (Abcam, ab25333, 1:100); COX-2 (Cambridge bioscience, aa570-598, 1:100); Ym-1 (StemCell 
Technology, 60130, 1:200); CD206 (Abcam, ab8918, 1:100); Ly6G (Biolegend, Clone A18, 1:100); 
B220 (Biolegend, 103202, 1:50). Secondary-HRP conjugated antibodies were incubated for 30 
minutes at RT. Staining was developed using diaminobenzidine and counterstained with hematoxylin. 
For CD8 staining VECTASTAIN® Elite® ABC-HRP Kit (Peroxidase, Rat IgG) (Vector laboratories) 
was used. 
Picrosirius red staining 
Paraffin embedded murine liver samples were de-waxed and hydrated using a graded ethanol series. 
Tissue sections were then treated with 0.2% phosphomolybdic acid and subsequently stained with 0.1 
% Sirius red F3B (Direct red 80)(Sigma Aldrich) in saturated picric acid solution for 90 minutes at RT . 
Tissues were then rinsed twice in acidified water (0.5% glacial acetic acid) (Sigma Aldrich) before and 
after the staining with 0.033 % fast green FCF (Sigma Aldrich). Finally, tissues were dehydrated in 
three changes of 100 % ethanol, cleared in xylene and mounted. Picrosirius red staining was 
quantified using Image J software. 
Human tissue samples 
Paraffin embedded human tissue sections from control healthy subjects, primary PDAC tumors and 
PDAC liver metastasis were obtained from the Liverpool Tissue Bank, University of Liverpool, UK. All 
patients were treatment naïve (no prior chemotherapy). Patient samples were collected after obtaining 
written informed consent from patients under the frame of the Declaration of Helsinki. All samples 
were pathologically confirmed. All studies involving human tissues were approved by the University of 
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Liverpool and by National Research Ethics (Research Integrity and Governance Ethics committee 
North West Cheshire Reference: REC15/NW/0477). 
 Statistical analysis 
Statistical analysis of experiments with two groups was performed using a two-tailed unpaired 
Student’s t-test with 95% confidence interval. Statistical analysis of experiments with more than two 
groups was performed using nonparametric analysis of variance (ANOVA) test with comparisons 
between groups using Bonferroni’s multiple comparison test. All statistical analysis were performed 
using GraphPad Prism software, p<0.05 was considered significant. Statistical significance is 
indicated in the figures as follows: ***, p<0.001; **, p< 0.01; *, p< 0.05; n.s., not significant. 
Histograms are shown as mean ± SEM. The following numbers (n) of fields of views (FoV) were 
analyzed for each tissue section staining: Fig. 1A (n=3), Fig. 1C (n=5), Figs. 2 D-F (n=5), Fig. 3B 
(n=4), Fig. 4C (n=4),  Figs. 4D-G(n=5), Figs. 5E,F (n=5), Figs. 6A,E (n=5), Figs. 7C,D (n=6), 
Supplementary Figs. S1A,B (n=3), Supplementary Figs. S2B,D,E (n=5), Supplementary Fig. S3I 
(n=4), Supplementary Figs. S4F,G,H,I,J,L,M (n=5), Supplementary Figs. S5D-K (n=6), Supplementary 
Fig. S5P (n=4), Supplementary Figs. S6B-D (n=6), Supplementary Fig. S6E (n=4), Supplementary 
Figs. S6H-J (n=6), Supplementary Figs. S7 C,D (n=6), Supplementary Fig. S8C (n=3). 
 
Results 
CD8
+
 T cell function and infiltration are lost during metastatic progression 
To investigate whether anti-tumor immunity might affect PDAC metastasis, we first analyzed by 
immunohistochemistry (IHC) technique liver biopsies from advanced metastatic PDAC patients, and 
healthy livers. In metastatic PDAC liver samples, large metastatic lesions with high numbers of 
cytokeratin positive (CK
+
) tumor cells (CK
+
 rich) showed few infiltrating CD8
+
 T cells. In contrast, 
smaller metastatic tumor deposits (CK
+
 poor) were rich in CD8
+
 T cells (Figs. 1A,B; Supplementary 
Fig. S1A). Similarly, small spontaneous metastatic lesions generated in Kras
G12D
;Trp53
R172H
;Pdx1-Cre 
(KPC) mice (27) showed higher CD8
+
 T cell infiltration compared to larger established lesions 
(Supplementary Fig. S1B).  
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To further evaluate the changes in CD8
+
 T cell infiltration during PDAC metastasis, we next 
induced liver metastasis by intrasplenic implantation of KPC-derived pancreatic cancer cells 
expressing the dual reporter gene zsGreen and firefly luciferase (KPC
zsGreen/luc
) (25,26,29). In 
agreement with the data obtained in PDAC patients and the autochthonous KPC model, small 
metastatic lesions, mainly found at the early stage of metastatic progression (6 days post intrasplenic 
implantation, d6) and characterized by low numbers of KPC cancer cells, showed high infiltration of 
CD8
+
 T cells in comparison to tumor free livers. In contrast, large metastatic lesions with abundant 
cancer cell numbers, mainly found at a later stage of metastasis progression (14 days post 
intrasplenic injection, d14), showed a significant loss of CD8
+
 T cells (Figs. 1C-E). To assess whether 
the identified CD8
+
 T cells were active, we next stained for the T cell activation marker CD69 and the 
inhibitory immune checkpoint receptor PD-1. CD8
+
 T cells from small tumors (d6) were active (CD69
+
 
and PD-1
-
), while CD8
+
 T cells isolated from large metastatic tumors (d14) were inactive (CD69
-
 and 
PD-1
+
) (Figs. 1F,G; Supplementary Fig. S1C). Gene expression analysis of the cytolytic factors Tnfa 
and Gzmb in metastasis infiltrating CD8
+
 T cells positive for PD-1 confirmed that the few infiltrating 
CD8
+
 T cells in large metastatic lesion (day 14) were also exhausted (Fig. 1H). Collectively, these 
results indicate that CD8
+
 T cells are able to infiltrate small metastatic tumors but that during 
metastatic progression CD8
+
 T cell infiltration and cytotoxic function are lost.  
 
Immunosuppressive M2-like metastasis associated macrophages (MAMs) accumulate during 
PDAC metastasis 
Tumor and metastasis associated macrophages can restrict CD8
+
 T cell effector functions 
depending on their activation state (16,30). Since large numbers of metastasis associated 
macrophages (MAMs) can be found at the hepatic metastatic site in PDAC (26), we next analyzed 
gene expression of M1- and M2-like activation markers in isolated MAMs (Supplementary Fig 2A). 
While we did not observe a significant difference in MAM numbers (Fig. 2A), MAMs isolated from 
small metastatic tumors (d6) revealed higher expression of immune stimulatory genes (C-X-C motif 
chemokine 10, Cxcl10; interleukin 12, Il2; interferon gamma, Ifng) and genes associated with antigen 
presentation (H2Aa; Cd86), resembling a pro-inflammatory M1-like phenotype (Fig. 2B). In contrast, 
macrophages isolated from large metastatic tumors (d14) significantly upregulated the expression of 
immunosuppressive (transforming growth factor beta, Tgfb, Arginase, Il10) and anti-inflammatory M2-
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like markers (mannose receptor C-type 1, Mrc1, resistin-like-α, Retnla) (Fig. 2C). Analysis of small 
metastatic tumor tissue sections confirmed a  higher number of myeloid-like cells expressing 
prototypical pro-inflammatory markers, including inducible nitric-oxide synthase (iNOS), major 
histocompatibility complex class II (MHC-II) and cyclooxygenase-2 (COX-2) (Fig. 2D). On the 
contrary, larger established metastatic tumors contained a higher number of myeloid-like cells 
expressing M2-like alternative activation markers, such as macrophage mannose receptor 1 (CD206) 
and Chitinase-like protein 3 (Ym-1) (Fig. 2E), and M2-like (RELM
+
) MAMs accumulated in close 
proximity to disseminated cancer cells (zsGreen) (Fig. 2F).  
Since M2-like macrophages can execute potent inhibitory effects on cytotoxic CD8
+
 T cell 
functions (30), we next explored the apoptotic rate of disseminated tumor cells. We observed a higher 
apoptotic rate (cleaved caspase 3
+
) of cancer cells in small metastatic lesions (d6) compared to large 
metastatic lesions (d14) (Supplementary Fig. S2B). Moreover, MAMs isolated from established 
metastatic lesions significantly suppressed CD8
+
 T cell proliferation (Fig. 2G) and activation ex vivo 
(Fig. 2H), compared to MAMs isolated from small metastatic lesions.  
Together, these data suggest that metastatic progression in PDAC is accompanied by the 
reprogramming of MAMs towards an M2-like immunosuppressive phenotype that can inhibit cytotoxic 
CD8
+
 T cell functions.  
 
Pharmacological blockade of the CSF-1/CSF-1R axis reprograms MAMs towards an immune-
stimulatory phenotype and restores CD8
+
 T cell mediated anti-tumor immunity in metastatic 
PDAC  
Based on our findings, we reasoned that blocking the rewiring of M1-like MAMs into 
immunosuppressive M2-like MAMs during metastatic progression could sustain tumoricidal CD8
+
 T 
cell functions and subsequently inhibit PDAC metastasis. Colony stimulating factor 1 (CSF-1) and its 
cognate receptor CSF-1R are among the most advanced targets to inhibit tumor promoting 
macrophage functions in cancer (19,31). CSF-1 is abundantly expressed by metastatic pancreatic 
cancer cells (Supplementary Fig. S2C) and CSF-1R is expressed by MAMs in experimental and 
spontaneous PDAC metastasis models (Supplementary Figs. S2D,E). To assess whether the 
inhibition of CSF-1 affects MAM functions, T cell infiltration/activation, and metastatic PDAC 
progression, we induced hepatic metastasis by intrasplencially implanting KPC cells. Starting at d7, 
16 
 
we administered neutralizing anti-CSF-1 monoclonal antibody (CSF-1) for 2 weeks (Fig. 3A). CSF-
1 treatment reduced metastatic tumor burden (Fig. 3B). In respect to MAMs, CSF-1 reduced not only 
overall MAM numbers (Fig. 3C), but specifically reduced the number of M2-like F4/80
+
CD206
+
 MAMs 
(Fig. 3D). Gene expression analysis of MAMs further confirmed that inhibition of CSF-1 induces a 
reprogramming of MAMs towards an inflammatory M1-like phenotype (Fig. 3E). Consistent with a 
rewired pro-inflammatory metastatic microenvironment, CD8
+
 T cell numbers and function were 
increased in CSF-1 treated mice (Figs. 3F-I). It is noteworthy that CSF-1 treatment also enhanced 
the proliferation rate (Ki67
+
) within PD-1
+
CD8
+
 T cells, suggesting a partial reinvigoration of exhausted 
PD-1
+
 CD8
+ 
T cells within the metastatic niche (Fig. 3J). Tumor bearing mice treated with a small 
molecule inhibitor of CSF-1R (BLZ945) (32) showed a similar reduction in the metastatic tumor 
burden (Supplementary Figs. S3A-E) accompanied by an increase of pro-inflammatory M1-like MAMs 
(Supplementary Figs. S3F,G) and CD8
+
 T cells in metastatic livers (Supplementary Fig. S3H), and an 
increase in apoptosis of metastatic cancer cells (Supplementary Fig. S3I) in vivo. 
Pharmacological depletion of CD8
+ 
T cells abolished the anti-metastatic effect of CSF-1 (Fig. 3K; 
Supplementary Figs. S3J,K) demonstrating that the ability of MAMs to support PDAC metastasis is in 
part due to their capacity to suppress cytotoxic CD8
+
 T cells.   
Taken together, our findings show that MAM targeted therapies can restore a pro-inflammatory 
environment in metastatic PDAC in which cytotoxic CD8
+
 T cells can infiltrate and kill metastatic 
cancer cells.  
 
CSF-1 inhibition reduces desmoplasia and sensitizes metastatic PDAC to αPD-1 treatment. 
Since CSF-1 restores T cell infiltration in metastatic tumors (Fig. 3) we next evaluated whether 
PD-1 treatment could further improve the anti-tumorigenic effect of CSF-1. To test this, we treated 
tumors early (d7), or later (d14), after T cell infiltration is lost (Fig. 1; Fig. 4A). In response to early 
intervention (d7), metastatic tumour progression was significantly inhibited by both agents delivered 
as monotherapies (PD-1=49 ±3%; CSF-1=50+/-3%), but the anti-tumorigenic effect of CSF-1 
treatment was further potentiated when administrated in combination with PD-1 (CSF-1/PD-1=80 
±3%) (Fig.4B). In contrast, in response to a later intervention on larger metastatic lesions (d14), 
neither PD-1 nor CSF-1 alone was able to reduce metastatic tumor burden (KPC: PD-1=3 ±3%; 
CSF-1=22 ±2%; Panc02: PD-1=5 ±3%; CSF-1=21 ±4%) (Fig. 4B). In large metastatic lesions, 
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only combinatorial treatment of CSF-1/PD-1 was able to reduce metastatic tumor burden by 61 
±4% (KPC) and 55 ±3% (Panc02), respectively (Fig. 4B). Early intervention showed a better response 
(improved by an additional 20 ±8%) to combinatorial αCSF-1/αPD-1 therapy compared to later 
intervention. To address whether impaired drug delivery and/or the difference in treatment regimen 
might have caused the inferior response to therapy at the later intervention, we next directly 
compared the anti-tumoral activity of MAMs isolated from tumors exposed to αCSF-1 and αPD-1 early 
(starting d7) versus late (starting d14) intervention. The adoptive transfer of isolated MAMs reduced 
metastatic tumor progression (Supplementary Figs. S4A,B), increased the presence of M1-like MAMs 
and CD8
+
 T cells (Supplementary Figs. S4C-E) in comparison to control mice which did not receive an 
adoptive transfer of MAMs. However, minimal differences were found between mice receiving MAMs 
from the early treatment versus late treatment, suggesting that the inferior effect of anti-CSF-1/PD-
1 therapy at late intervention (compared to early intervention) was due to a more advanced stage of 
metastatic progression and to the poor infiltration of CD8
+
 T cells observed in large lesions, and not 
due to an impairment in drug delivery or differences in treatment regimens. 
Previous studies suggest that myofibroblasts and collagen deposition can impair T cell infiltration in 
primary tumors (14,33). Thus, we hypothesize that targeting MAMs by CSF-1 treatment may 
decrease myofibroblast accumulation and collagen deposition, thereby supporting T cell infiltration 
and subsequently increase PD-1 efficacy. To address this question we first assessed the spatial 
localization of CD8
+
 T cells in advanced PDAC metastatic tumors from patients and mice. Advanced 
metastatic human tumors had low numbers of intra-metastatic CD8
+
 T cells and the majority of CD8
+
 
T cells presented in these tumors accumulated at the periphery of metastatic lesions, where typically 
high numbers of myofibroblasts (SMA
+
) are found (Fig. 4C). Similar, large murine metastatic lesions 
(d14), showed an increase in SMA
+
 myofibroblasts, collagen deposition, that correlates with a 
decrease in CD8
+
 T cell infiltration (Fig. 4D). 
In line with our hypothesis, inhibition of CSF-1 altered the desmoplastic reaction at the metastatic 
site. In fact, KPC and Panc02 tumors treated with CSF-1 alone or in combination with PD-1 
markedly reduced collagen deposition (Fig. 4E; Supplementary Figs. S4F-H), SMA
+ 
myofibroblast 
numbers (Fig. 4F; Supplementary Figs. S4I,J), and increased CD8
+
 T cell infiltration (Fig. 4G; 
Supplementary Figs. S5K-M) independently of the time of treatment intervention.  
18 
 
Taken together, these data suggest that reducing the fibrotic reaction by targeting macrophages 
increases CD8
+
 T cell infiltration and response to PD-1 therapy.  
 
CSF-1 inhibition reduces granulin expression in macrophages in vitro and in vivo. 
We previously identified macrophage-derived granulin as a key effector protein for SMA
+
 
myofibroblast accumulation during PDAC metastasis (26). Granulin is a secreted glycoprotein that 
stimulates fibroblast activation and migration (34,35). Thus, we next asked whether inhibition of CSF-
1 could impair the expression of granulin in macrophages.  We found that recombinant CSF-1 is a 
strong inducer of granulin expression in primary bone marrow derived macrophages (BMMs) (Fig. 5A) 
and that elevated granulin secretion correlates with alternatively (M2-like) activated macrophages 
(Supplementary Fig. S5A). Pancreatic cancer cells, which abundantly secrete CSF-1 (Fig. 5B), 
induced the expression of granulin in macrophages in a CSF-1 dependent manner (Fig. 5C). 
Accordingly, macrophages isolated from CSF-1 treated metastatic tumors have reduced granulin 
expression (Fig. 5D,E).  
Hypoxia is a hallmark of cancer and hypoxia supports tumor promoting functions of macrophage 
(36,37). Thus, we next studied whether hypoxia affects granulin expression in macrophages during 
PDAC metastasis. Hypoxia progressively increased during PDAC metastasis (Fig. 5F). In vitro 
treatment with the chemical hypoxia mimetic dimethyloxaloglycine (DMOG) (38) or hypoxic culture 
conditions (1% O2) increased granulin secretion by macrophages (Figs. 5G,H).  Importantly, hypoxic 
culture conditions markedly amplified the granulin-inducing effect of CSF-1 (Fig. 5H). In an attempt to 
test the role of tumor hypoxia in increasing granulin expression in vivo, we treated tumor bearing mice 
with digoxin, a translational inhibitor of hypoxia-inducible factors 1  (HIF-1) (39). Administration of 
digoxin reduced metastatic tumor burden, prevented granulin expression, inhibited SMA
+
 
myofibroblast accumulation, increased CD8
+
 T cell numbers, and increased the presence of M1-like 
MAMs, while total MAM numbers remained unchanged (Supplementary Figs. S5B-K).   
Taken together, these results demonstrate that CSF-1 induces granulin expression in macrophages, 
which can be further amplified under hypoxic conditions. 
 
Genetic depletion of granulin restores CD8
+
 T cell infiltration in metastatic tumors, but T cell 
dysfunctionality remains. 
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Since inhibition of CSF-1 reduces granulin expression, we evaluated the effect of granulin 
depletion in regulating T cell infiltration. Therefore we intrasplenically injected KPC-derived cells into 
chimeric mice deficient of granulin (Grn
-/-
) in the bone marrow (BM) compartment (WT+ Grn
-/-
 BM 
mice). Intra-metastatic CD8
+
 T cell accumulation was improved in granulin deficient mice (Figs. 6A,B) 
which are defective in myofibroblast activation (Figs. 6A,C). Moreover, by comparing metastatic 
lesions of equal sizes in WT and Grn
-/-
 mice, we found an increase of adoptive transferred 
tdTomatoRed (tdTR) CD8
+
 T cells in the intra-metastatic area of granulin deficient tumours compared 
to WT (Figs. 6D,E). Overall hematopoietic (CD45
+
), T (CD3
+
), neutrophil (Ly6G
+
), macrophage 
(F4/80
+
) and B (B220
+
) cell numbers remained unchanged in granulin deficient metastatic tumours 
(Supplementary Figs. S5L-P). Although in granulin deficient mice we did not observe a difference in 
CD8
+
 T cell numbers (Fig. 6F) nor in their activation state (Fig. 6G), we queried whether granulin 
might affect T cell functions directly or indirectly through the activation of hepatic stellate cells. 
Recombinant granulin did not have a direct effect on T cell functions in vitro, while macrophages 
lacking granulin retained their CD8
+ 
T cell suppressive capacity (Fig. 6H, I). In contrast, conditioned 
media collected from activated hepatic stellate cells reduced CD8
+
 T cell activation (Fig. 6J) and 
proliferation (Fig. 6K).   
Taken together, our results suggest that depletion of granulin improves CD8
+
 T cell infiltration into 
metastatic tumors, but it does not directly affects their function. 
 
Depletion of granulin restores the response of metastatic PDAC to αPD-1 therapy. 
To test whether the observed increase in CD8
+
 T cell entry into granulin deficient metastatic 
tumors might improve their response to PD-1 therapy, we treated tumor bearing WT and Grn
-/- 
mice 
with either PD-1 or IgG control antibody (Fig. 7A). Metastatic tumor burden was quantified by in vivo 
bioluminescence imaging (BLI) techniques at day 14 prior treatment and at endpoint (day 24). While 
single agent PD-1 therapy did not show any efficacy in WT tumors, PD-1 treatment in Grn
-/- 
mice 
caused a dramatic decrease in metastatic progression, with even partial regression (Fig. 7B,C, 
Supplementary Fig. S6A). As expected, no changes in myofibroblast accumulation and CD8
+
 T cell 
infiltration were detected in WT tumors in the presence or absence of PD-1. In contrast, in Grn
-/-
 
tumors which are deficient in myofibroblast accumulation, CD8
+
 T cell numbers significantly increased 
upon PD-1 treatment (Figs. 7D-F). Moreover, PD-1 treatment did not alter GzmB nor IFN 
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expression levels in CD8
+
 T cells isolated from WT tumors, while depletion of granulin led to a 
significant upregulation of GzmB and IFN expression in CD8
+
 T cells in response to PD-1 
administration (Figs. 7G,H).  
Interestingly, we found in granulin deficient tumors treated with PD-1 an increased presence of 
immune stimulatory MAMs that expressed pro-inflammatory markers iNOS, MHC-II, and COX-2 (Fig. 
7I; Supplementary Fig. S6B). Reciprocally, these tumors displayed lower numbers of 
immunosuppressive Ym-1
+
 and CD206
+
 MAMs compared to untreated Grn
-/-
 tumors (Fig. 7J; 
Supplementary Fig. S6C) while total macrophage numbers remained the same (Fig. 7K; 
Supplementary Fig. S6D).  These findings suggest that the observed increase in IFNexpression by 
CD8
+
 T cells in PD-1 treated granulin deficient mice promotes an immune stimulatory M1-like MAM 
phenotype, allowing them to further fuel an anti-tumor immune attack. 
Although both CSF-1 inhibition and granulin depletion are able to restore cytotoxic T cell infiltration 
in metastatic tumors, PD-1 treatment was more effective in granulin deficient tumors (Fig. 7B) 
compared to WT tumors treated with CSF-1 (Fig. 4B, d14). Thus, these tumors might still be 
immunologically different and respond differently to immunotherapy. A recent study revealed that 
blockade of CSF-1R expressed on cancer associated fibroblasts can induce the accumulation of 
immunosuppressive Ly6G
+
 cells, thereby counteracting the therapeutic benefit of CSF-1R and/or 
PD-1 inhibition (40). In agreement with these studies, we found that CSF-1 treatment increases the 
infiltration of Ly6G
+
 cells in metastatic tumors, while granulin depletion did not have this effect 
(Supplementary Fig. S6E). Moreover, while CSF-1 inhibition improved PD-1 response in WT mice, it 
rather had a counteracting effect in granulin deficient mice treated with PD-1 (Supplementary Figs. 
S6F-J).   
Taken together, these findings demonstrate that depletion of granulin dramatically improves the 
response of metastatic pancreatic tumors to PD-1 treatment in vivo and that targeting a macrophage 
secreted factor such as granulin might be more effective than targeting macrophages. 
To further confirm that the increase in CD8
+
 T cell infiltration and the improved response to PD-1 
in granulin deficient mice is dependent on reduced fibrosis, we next treated tumor bearing mice with 
the Vitamin D analogue Calcipotriol (Cal), an agent which has previously been shown to revert 
activated stellate cells to quiescence resulting in reduced fibrosis in pre-clinical mouse models (41). 
Indeed, administration of Cal improved the efficacy of PD-1 therapy (Supplementary Figs. S7A,B). 
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Tumors treated with Cal had reduced fibrosis (Supplementary Fig. S7C) and decreased hepatic 
stellate cell activation, while CD8
+
 T cell infiltration was improved (Supplementary Fig. S7D).  
Taken together, these data suggest that granulin-induced fibrosis impedes CD8
+
 T cell infiltration 
and impairs the effectiveness of PD-1 therapy, and that restoration of CD8
+
 T cell infiltration via 
granulin depletion/inhibition or possibly via inhibition of other pro-fibrotic factors is a prerequisite for 
successful PD-1 therapy in metastatic pancreatic cancer. 
 
Discussion 
The data presented herein describe that macrophage-derived granulin is a critical inducer of T cell 
exclusion in metastatic PDAC, and provide pre-clinical data that support the rational for targeting 
granulin in combination with immune checkpoint blocker αPD-1 for the treatment of metastatic PDAC 
(Supplementary Fig. S8A).  
During cancer progression, immune evasion is a fundamental mechanism which allows malignant 
tumor cells to escape destruction by the effector cells of our immune system (1). A recent study 
described how the presence of tumor infiltrating CD8
+
 T cells together with the presence of 
neoantigen numbers stratifies PDAC patients with the longest survival; emphasizing the critical role of 
CD8
+
 T cell in inhibiting PDAC progression (42). In our study we observed that CD8
+
 T cell function 
and infiltration are lost during metastatic progression. Large human and mouse PDAC tumors, both at 
the primary (Supplementary Figs. S8B,C) (3) and at the metastatic site (Fig. 1), are poorly infiltrated 
by CD8
+
 T cells and are characteristically surrounded by high numbers of granulin secreting MAMs 
and a dense fibrotic stroma (13,20). We could speculate that similar to the metastatic site, 
macrophage derived granulin promotes CD8
+
 T cell exclusion also at the primary tumor. However, 
further investigations are needed.  
The importance of targeting the immunosuppressive TME in PDAC to obtain clinical benefit from 
immunotherapy is becoming increasingly more evident (43). However, central to the efficacy of 
immune checkpoint blockade is the requirement for cytotoxic CD8
+
 T cells to infiltrate into tumors 
(1,15). Indeed, in our studies we find that metastatic PDAC lesion become sensible to αPD-1 therapy 
only in the presence of reduced fibrosis mediated by CSF-1, granulin depletion or calcipotriol 
treatment. 
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Dependent on the microenvironmental cytokine milieu, macrophages are not only promoting tumor 
growth, but they can also critically orchestrate an anti-tumor immune response (30). 
 Therapies that aim to specifically inhibit the pro-tumorigenic functions of macrophages, while sparing 
and/or enhancing their tumoricidal activity, could act as an alternative, and perhaps, more efficient 
approach than therapies that reduce macrophage numbers in tumors (44,45). In this regard, our 
studies indicate that depletion of granulin is sufficient to restore T cell infiltration at the metastatic site 
and that granulin deficient mice show a remarkable response to PD-1 treatment accompanied by 
increased numbers of M1- like macrophages.  Thus, in the presence of PD-1, the immune system in 
granulin deficient mice can access an abundant number of macrophages for their reprogramming 
towards an immune stimulatory M1-like phenotype, which facilitates the mounting of an effective 
immune response against cancer. 
  
In conclusion, our studies uncover a mechanism by which metastatic PDAC tumors evade the 
immune response and provide the rationale for targeting granulin and other factors promoting hepatic 
fibrosis, in combination with immune checkpoint inhibitors for the treatment of metastatic PDAC. 
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Figure Legends  
 
Figure 1: CD8+ T cell infiltration and activation is lost during metastatic PDAC 
progression 
(A-B) Immunohistochemistry images and quantification of cytokeratin (CK)
+
 metastatic cancer cells 
and cytotoxic T cells (CD8
+
) infiltration in human serial tissue sections (n = 10 metastatic PDAC; n = 5 
healthy; each metastatic PDAC tissue section contained multiple lesions. Individual lesions were 
captured by one field of view (FoV).  Dots represent the relationship between CD8
+
 T cell numbers 
and CK
+ 
cell numbers in each lesion; (C-H) Liver metastasis was induced by intrasplenic implantation 
of KPC
zsGreen/luc 
cancer cells. Livers were resected from metastatic mice after 6 and 14 days. (C-D) 
Individual lesions were captured by one FoV. Dots represent the relationship between CD8
+
 T cell 
numbers and KPC
zsGreen/luc
 cancer cell numbers in each lesion (n=4 mice / time point, five FoV 
quantified / mouse) (E) Percentage of CD8
+ 
T cells, (F) CD69
+
 CD8
+ 
T cells, (G) and PD-1
+
 CD8
+ 
T 
cells over time assessed by flow cytometry analysis. (H) Quantification of Tnfa and Gzmb mRNA 
levels in PD-1
+
 and PD-1
neg
 CD8
+ 
T cells isolated by fluorescence activated cell sorting (FACS) from 
livers resected at day 14.  Scale bars = 100µm; ***, P<0.001; **, P < 0.01; *, P < 0.05; n.s., not 
significant, by unpaired t-test and/or Bonferroni multiple comparison. 
 
 
Figure 2: Immune suppressive macrophages accumulate in established PDAC 
metastasis. 
Liver metastasis was induced by intrasplenic implantation of KPC
 luc/zsGreen
 cancer cells. Livers were 
resected 6 and 14 days (n= 4 mice / time point) and analyzed. (A) Flow cytometry quantification of 
F480
+
 cells in naïve and metastatic resected livers. (B-C) M1 and M2-macrophage associated genes 
expression in FACS isolated MAMs by qPCR. (D) Immunohistochemistry images and quantification of 
M1-like MAM markers and (E) M2-like MAM markers. (F) Immunofluorescent images and 
quantification of RELMα
+ 
M2-like macrophages clustering around metastatic PDAC cells 
(zsGreen
+
).(G-H) MAMs isolated from resected livers were tested for their ability to (G) suppress 
CD28/CD3 Dynabeads (DB) stimulated splenic CD8
+
 T cell proliferation (CFSE dilution) (H) and 
activation (IFNγ level) (data are mean ± SD of 4 independent experiments). Scale bars= 100µm; ***, 
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P<0.001; **, P < 0.01; *, P < 0.05; n.s., not significant, by unpaired t-test and/or Bonferroni multiple 
comparison. 
 
Figure 3: Pharmacological blockade of CSF-1 reprograms MAMs and reinvigorates 
CD8+ T cell functions 
Liver metastasis was induced by intrasplenic implantation of KPC
zsGreen/luc
 cells. After 7 days mice 
were treated with IgG control (Ctr) or CSF-1 antibody. Metastatic livers were resected at day 20 and 
analyzed by haematoxylin and eosin (H&E) staining (n=6 mice/group) and by flow cytometry (n=4 
mice/group). (A) Schematic illustration of the experiment. (B) H&E images and quantification. (C) 
Total and (D) M2-like (CD206
+
) MAMs. (E) M1-like and M2-like macrophage genes expression 
analysis in MAMs (F) Quantification of CD8
+
 T cells. (G) Representative dot plot and quantification of 
IFN levels in CD8
+
 T cells (n = 3 mice /group); Quantification of (H) Granzyme B
+
 (GzmB) cells, (I) 
proliferating (Ki67
+
) cells among total CD8
+
 T cells and among (J) PD-1
+
 CD8
+
 T cells. (K) Metastatic 
tumor burden in mice treated with CD8 and CSF-1 alone or in combination (n = 3 mice /group).  
Scale bars = 100µm; ***, P<0.001; **, P < 0.01; *, P < 0.05; n.s., not significant, by unpaired t-test 
and/or Bonferroni multiple comparison. 
 
Figure 4: CSF-1 inhibition reduces desmoplasia and sensitizes metastatic PDAC to 
αPD-1 treatment 
Liver metastasis was induced by intrasplenic implantation of KPC
zsGreen/luc
 cells or Panc02
zsGreen/luc 
cancer cells. Cohorts were treated with control IgG, CSF-1 and PD-1, alone or in combination. 
Treatment started at day 7 (d7) or at day 14 (d14) (n = 4 or 5 mice / group). (A) Schematic 
representation of the treatment regimen. (B) Percentage of average change in metastatic lesion area 
compared to control in response to treatment assessed by H&E staining at endpoint. (C) 
Immunohistochemistry images of CD8
+ 
T cells and myofibroblasts (αSMA
+
) in human PDAC 
metastatic livers and quantification of perimetastatic (P) and intrametastatic (IM) CD8
+
 T cells (n=  6 
patients). (D) Liver metastasis was induced by intrasplenic implantation of KPC
zsGreen/luc
 cancer cells. 
Livers were resected after 6 and 14 days and assessed by SMA
+
 (myofibroblasts), Picrosirius red 
(collagen deposition) and CD8
+ 
T cell staining. (E-G) Images and relative quantification of (E) 
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picrosirius red and H&E staining of sequential tumor sections showing area occupied by fibrotic 
stroma, (F)  myofibroblasts (SMA
+
, red) cell frequency and (G) infiltrating CD8
+
 T cells in liver tissue 
sections of mice treated at d14 with IgG control or CSF-1. Quantification of staining is referred to 
metastatic tumor generated by KPC
 zsGreen/luc
 or Panc02
 zsGreen/luc
 cancer cells implantation. Images are 
representative of KPC
 zsGreen/luc
 cancer cells derived liver metastatic lesions (n= 4 or 5 mice / group; 
additional treatment groups are shown in Supplementary Fig. S4). Scale bars= 100µm; ***, P<0.001; 
**, P < 0.01; *, P < 0.05; n.s., not significant, by unpaired t-test and/or Bonferroni multiple comparison. 
 
Figure 5: Hypoxia amplifies CSF-1-induced granulin expression in macrophages 
(A) Quantification of Granulin expression by qPCR in primary bone marrow derived macrophages 
(BMMs) unstimulated and exposed to recombinant CSF-1. (B) ELISA quantification of CSF-1 protein 
levels in conditioned medium (CM) generated from BMMs, and KPC and Panc02 pancreatic cancer 
cells. (C) Quantification of Granulin expression by qPCR in BMMs exposed to KPC and Panc02 
conditioned media (CM) in the presence of IgG control (Ctr) or neutralizing CSF-1 mAb. (D) 
Quantification of Granulin expression in MAMs from KPC
zsGreen/luc 
induced metastatic tumors treated 
with IgG control (Ctr) or CSF-1. (E) Immunohistochemistry images and quantification of granulin in 
KPC
zsGreen/luc
 or Panc02
 zsGreen/luc
 tumor bearing mice treated with IgG control (Ctr) or CSF-1 (n = 4 
mice). (F) Representative images and quantification of hypoxic areas surrounding metastatic 
KPC
zsGreen/luc
 cells (zsGreen
+
) assessed by Hypoxyprobe
TM
-1 (n= 3 mice / group). (G-H) ELISA 
quantification of (G) granulin protein level in unstimulated BMMs (Ctr), and BMMs exposed to 
recombinant murine CSF-1 or DMOG for 24 hours and (H) granulin protein level in BMMs cultured for 
24 hours under normoxic and hypoxic conditions in presence or absence of recombinant murine CSF-
1. In A-C, G-H data are mean ± SD of 3 independent experiments. Scale bars= 100µm; ***, P<0.001; 
**, P < 0.01; *, P < 0.05; n.s., not significant, by unpaired t-test. 
 
Figure 6: CD8+T cells intra-metastatic infiltration but not activity is increased in 
granulin depleted mice 
(A-C) Liver metastasis was induced by intrasplenically implantation of KPC cells into chimeric WT+ 
WT BM and WT+ Grn
-/-
 BM mice. Entire livers were resected 14 days later and analyzed. (A) 
Immunofluorescence images of CD8
+
 T cells and αSMA
+
 myofibroblasts. Intrametastatic (IM) and 
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peripheral areas (P) are indicated. (B) Quantification of peripheral (P) and intrametastatic (IM) CD8
+
 T 
cells. (C) Quantification of αSMA
+ 
cells (WT BM, n= 5; Grn
-/-
 BM, n= 6). (D-E) Adoptive transfer of 
tdTR CD8
+
 T cells into metastasis bearing WT and Grn
-/-
 mice (D) Schematic illustration of the 
experiment. (E) Immunofluorescence images and quantification of tdTR CD8
+
 T cells (red) in 
perimetastatic (P) and intrametastatic (IM) regions (n= 3 mice / group). (F-G) KPC cells were 
intrasplenically implanted in mice to induce liver metastasis in WT and Grn
-/-
 mice.  Livers were 
resected after 14 days and analyzed (n= 4 WT and n= 4 Grn
-/-
 mice). (F) Flow cytometry quantification 
of CD8
+
 T cell number and (G) IFN
+
 CD8
+
 T cell. (H-I) Bone marrow isolated macrophages (BMMs) 
derived from WT and Grn
-/-
 mice and recombinant granulin (rec. Grn) were tested for the capacity of 
suppress splenic CD8
+
 T cell (H) activation (IFN expression levels) and (I) proliferation (CFSE 
dilution). (J-K) Conditioned medium (CM) generated from activated hepatic stellate cells (HSC) was 
used to validate the (J) activation (IFN expression levels) and (K) proliferation (CFSE dilution) of 
splenic CD8
+
 T  cell in the presence or absence of a periostin neutralizing antibody. In H-K data are 
mean ± SD of 3 independent experiments. Scale bars= 100µm; ***, P<0.001; **, P < 0.01; *, P < 0.05; 
n.s., not significant, by unpaired t-test and/or Bonferroni multiple comparison. 
 
Figure 7: Depletion of granulin restores response of metastatic PDAC to αPD-1 
therapy 
Liver metastasis was induced by intrasplenic implantation of  KPC
zsGreen/luc
 cells in  WT and Grn
-/- 
mice. 
Mice were treated with control IgG or αPD-1.  Change in tumor burden was quantified by in vivo BLI.  
(n= 3 mice/group). (A) Schematic illustration of the experiment. (B) Change in metastatic tumor 
burden (total flux/sec). (C) H&E images of αPD-1 treated cohorts. Metastatic lesions are delineated 
with dashed lines. (D) Immunofluorescence images of myofibroblasts (αSMA
+
) and CD8
+
 T cell 
staining of sequential liver sections from WT and Grn
-/- 
mice treated with αPD-1. (E-F) Quantification 
of myofibroblasts (αSMA
+
) accumulation and CD8
+
 T cell infiltration as described in D. Quantifications 
of (G) Granzyme B (GzmB
+
) and (H) IFN
+
 CD8
+ 
T cells by flow cytometry analysis. (I-K) 
Immunohistochemistry images and quantification of cells positive for (I) pro-inflammatory M1-like 
(iNOS, MHC-II, COX-2) MAMs, (J) anti-inflammatory M2-like (Ym-1, CD206) MAMs and (K) total 
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(CD68) MAMs markers. Scale bars= 100µm; ***, P<0.001; **, P < 0.01; *, P < 0.05; n.s., not 
significant, by unpaired t-test and/or Bonferroni multiple comparison. 
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